Challenging and Changing Times

Times are undoubtedly tough for VCs investing in life sciences. Exits are few and far between. The public markets remain closed and, in terms of trade sales of VC-backed private pharma/biotech companies during H1/09, HBM Partners report that both the number and volume of transactions reached new lows (Read HBM’s survey here). The market is not however an excuse for poor returns and well-chosen, well-managed investments continue to return significant value to portfolios. In order to deliver the returns promised to LPs, it has never been more critical to be able to source, diligence and exit investments on a global basis.

Biolauncher has the operational expertise to help investors diligence, develop and find commercial partners for their investments. Our information, global networks and industry knowledge are powerful resources to draw upon to maximize your returns. We have worked with a range of VC and private equity groups to provide scientific, operational and market input into investment and portfolio decision making.

In addition to a wide network of contacts in the investment community, Rowan is a member of the European advisory board for Astia and chairs its European Life Science subcommittee:

Astia is a global network of entrepreneurs, advisors and investors that is committed to building women leaders and accelerating the funding and growth of high-potential, high-growth, women-led startups. Astia Client companies have raised over $940M since 2003  and have achieved 21 exits including 2 IPOs.

Biolauncher is a member of the Rock Spring Ventures’ (RSV) global network. RSV is an early stage, life science venture capital fund focusing on proprietary life science companies in the United States and United Kingdom. RSV’s initial investors include several of Japan and Korea’s leading corporations and financial institutions. These investors help provide an important bridge to key markets in East Asia.

Biolauncher provides analytical and due diligence services to the fund. To find out more about RSV’s unique investment model visit their web site.

Biolauncher is a member of  the Rock Spring Ventures' (RSV) global network. RSV is an early stage, life science venture capital fund focusing on proprietary life science companies in the United States and United Kingdom. RSV's initial investors include several of Japan and Korea's leading corporations and financial institutions. These investors help provide an important bridge to key markets in East Asia.  

Biolauncher provides analytical and due diligence services to the fund. To find out more about RSV's unique investment model visit their web site at www.rockspringventures.com.